Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma. - Rawson, R.V.; Maher, N.G.; Menzies, A.M.; Lo, S.N.; Mesbah Ardakani, N.; Jackett, L.A.; Vergara, I.A.; Pennington, T.E.; Shannon, K.F.; Ch'ng, S.; Gonzalez, M.; Burton, E.M.; et al. (Annals of Oncology, 2026)